Developing In Vivo Infection Models with MDR Pathogens for Evaluating Compound Efficacy
Publisher
Springer Singapore
Reference40 articles.
1. Akers, K., Mende, K., Cheatle, K. A., Zera, W. C., Yu, X., Beckius, M. L., Aggarwal, D., Li, P., Sanchez, C. J., Wenke, J. C., Weintrob, A. C., Tribble, D. R., Murray, C. K., & and the Infectious Disease Clinical Research Program Trauma Infectious Disease Outcomes Study Group. (2014). Biofilms and persistent wound infections in United States military trauma patients: a case-control analysis. BMC Infectious Diseases, 14, 190–200. 2. Alder, J., Li, T., Yu, D., Morton, L., Silverman, J., Zhang, X.-X., Critchley, I., & Thorne, G. (2003). Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection. Antimicrobial Agents and Chemotherapy, 47(11), 3562–3566. 3. Centers for Disease Control and Prevention. (2013). https://www.cdc.gov/drugresistance/biggest_threats.html 4. Chemotherapy (Proceedings of the 9th International Congress of Chemotherapy held in London, July, 1975);KR Comber,1976 5. Comber, K. R., Basker, M. J., Osborne, C. D., & Sutherland, R. (1977). Synergy between ticarcillin and tobramycin against Pseudomonas aeruginosa and Enterobacteriaceae in vitro and in vivo. Antimicrobial Agents and Chemotherapy, 11(6), 956–964.
|
|